Oct4、Stat3在卵巢浆液性/黏液性囊腺癌中的表达及临床意义

目的:探讨Oct4、Stat3在卵巢浆液性/黏液性囊腺癌中的表达及其相关性。 方法:应用组织芯片，采用免疫组化SP法检测60例卵巢浆液性/黏液性囊腺癌组织中Oct4、Stat3的表达。结果:Oct4在卵巢浆液性/黏液性囊腺瘤中的阳性表达率为35.0%（7/20），低于卵巢浆液性/黏液性囊腺癌中的83.3%（50/60），两者有显著统计学差异（P<0.01）。卵巢浆液性/黏液性囊腺癌中Oct4的阳性表达率与患者年龄、临床分期、组织学分化程度、患者组织学类型均无相关性（P>0.05）。Stat3在卵巢浆液性/黏液性囊腺癌阳性表达率为71.7%（43/60），明显高于卵巢浆液性/黏液性囊腺瘤中的35.0%（7/20），两者有显著统计学差异（P<0.01）。Stat3在Ⅰ、Ⅱ期癌中的阳性表达率低于Ⅲ、Ⅳ期癌（P<0.05），在中、低分化癌中的阳性表达率高于高分化癌（P<0.05），与患者组织学类型无关。卵巢浆液性/黏液性囊腺癌中Oct4表达与Stat3表达呈正相关（P<0.05）。结论:Oct4、Stat3高表达可能与卵巢浆液性/黏液性囊腺癌的发生、发展密切相关，且相互间可能具有协同作用。

The expressions and clinical significance of Oct4 and Stat3 in ovarian serous or mucinous cystadenoma or in cystadenocarcinoma

Objective:To explore the expression of Oct4 and Stat3 in ovarian serous or mucinous cystadenoma or in cystadenocarcinoma and the clinicopathologic significance.Methods:The expressions of Oct4 and Stat3 were detected by tissue microarray combined with SP immunohistochemistry in ovarian serous or mucinous cystadenoma or in cystadenocarcinoma.Results:The positive expression rate of Oct4 was 35.0% （7/20） in ovarian serous or mucinous cystadenoma,which was less than the 83.3% （50/60） in cystadenocarcinoma.There was significant difference between them （P<0.01）.But the rate of Oct4 expression in carcinoma was not associated with age,clinical stage,histological differentiation and histological types (P>0.05).The positive expression rate of Stat3 was 35.0% （7/20） in ovarian serous or mucinous cystadenoma,which was less than the 71.7%（43/60）in cystadenocarcinoma.There was significant difference between them （P<0.01）.The rate of Stat3 expression in carcinoma of gradeⅠ，Ⅱ was lower than grade Ⅲ，Ⅳ （P<0.05）.The positive expression rate of Stat3 was evidently higher in moderately and poorly differentiated carcinoma than that of the well differentiated group （P<0.05），and was not associated with histologic types.In ovarian serous or mucinous cystadenocarcinoma，there was a significantly positive correlation between Oct4 and Stat3 expression （P<0.05）.Conclusion:The overexpression of Stat3 and Oct4 may play an important role in the development and progression of ovarian serous or mucinous cystadenocarcinoma.